1. Introduction: A New Era in AF Management
Atrial Fibrillation (AF) remains the most common sustained arrhythmia encountered in clinical practice, and its footprint is expanding rapidly. Driven by an aging demographic and a rising tide of metabolic comorbidities, the prevalence of AF in the United States is projected to reach 12.1 million cases by 2030. This growth represents more than a statistical trend; it is a clinical call to action, as AF carries a 1.5- to 2-fold increased risk of mortality and a 5-fold risk of heart failure.
The 2023 ACC/AHA/ACCP/HRS Guidelines represent a paradigm shift in our clinical approach. We are moving away from viewing AF as an isolated rhythm disturbance to recognizing it as a complex "disease continuum." This evolution focuses on the underlying pathophysiological substrate and atrial myopathy, emphasizing that the management of AF must begin long before the first irregular heartbeat is recorded on an ECG.
Key Mission: To prioritize prevention, facilitate early intervention, and provide equitable, patient-centered care by managing AF across its entire spectrum of development.